Evidence Based Hair

Season 8 Episode 6: Uncovering the Link Between Weight Loss Medications and Hair Loss Nov 18, 2024

Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by Dr. Jeff Donovan, dermatologist and hair loss specialist. In this episode, Dr. Donovan delves into a fascinating study published in the Journal of the American Academy of Dermatology and Venereology, which explores the potential association between hair loss and the use of popular weight loss medications, such as semaglutide and terzepatide.

Dr. Donovan discusses the methodology and findings of the study, which utilized the FDA Adverse Event Reporting System to analyze reports of alopecia linked to these drugs. The episode highlights the importance of post-marketing research in uncovering side effects not initially apparent in clinical trials.

Join Dr. Donovan as he explains the statistical technique of disproportionality analysis used in the study, and its implications for understanding the potential hair loss risks associated with these medications. The episode also emphasizes the need for further research to better understand the timing, mechanism, and prevalence of hair loss among different patient groups.

Stay tuned for next week's episode, where Dr. Donovan will explore the effects of metformin on central centrifugal cicatricial alopecia, based on a recent study in JAMA Dermatology. Thank you for tuning in and supporting the Evidence-Based Hair Podcast, dedicated to advancing education and research in the complex world of hair loss.

STUDIES REFERENCED IN THIS EPISODE

Hannah Godfrey, Zachary Leibovit-Reiben, Patrick Jedlowski, Rebecca Thiede. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol . 2024 Jun 24. doi: 10.1111/jdv.20197. Online ahead of print.

Season 8 Episode 5: The Role of Terzepatide in Treating AGA Nov 11, 2024

Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist, Dr. Jeff Donovan. As the director of the Donovan Hair Academy, Dr. Donovan is dedicated to educating both the public and hair loss practitioners about the complexities of hair loss.

In this episode, Dr. Donovan delves into a fascinating study from JAAD Case Reports, which explores the potential benefits of the diabetes drug terzepatide for treating androgenetic alopecia. This groundbreaking case report suggests that medications targeting insulin resistance could offer new strategies for hair growth.

Join Dr. Donovan as he breaks down the study, discusses the implications of using GLP-1/GIP receptor agonists for hair loss, and highlights the importance of understanding the metabolic connections to androgenetic alopecia. Discover how these findings could pave the way for novel treatment approaches and what it means for patients worldwide.

Whether you're a practitioner, researcher, or someone affected by hair loss, this episode provides insightful perspectives on the future of hair loss treatment. Tune in to learn more about the potential of terzepatide and similar medications in addressing hair loss challenges.

STUDY REFERENCED

Gordon E, Musleh S, Bordone LA. Treatment of insulin resistance with tirzepatide leading to improvement of hair loss. JAAD Case Rep . 2024 Jun 11:50:123-125. doi: 10.1016/j.jdcr.2024.06.001. eCollection 2024 Aug.

Season 8, Episode 4: Unveiling the Risks: Steroid Injections and Vision Complications in Hair Loss Treatment Oct 28, 2024

Welcome to the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist, Dr. Jeff Donovan. In this episode, we delve into a crucial study exploring the unexpected side effects of steroid injections used in treating alopecia areata, particularly focusing on central serous chorioretinopathy (CSC). This condition, characterized by fluid accumulation beneath the retina, can lead to vision problems and retinal detachment.

Dr. Donovan reviews a compelling paper published in JAAD Case Reports, highlighting two cases where patients developed CSC after receiving steroid injections for hair loss. The episode emphasizes the importance of recognizing blurry vision as a potential warning sign and the need for immediate consultation with an eye specialist.

Join us as we discuss the implications of this study for hair loss specialists and the necessity of ongoing research to better understand the risks associated with long-term steroid use. Stay tuned for next week's episode, where we'll explore the role of tirzepatide in androgenetic hair loss treatment.

STUDIES REFERENCED IN THIS EPISODE

Deesha Desai, Ambika Nohria, Lina Alhanshali, Michael Buontempo, Kristen I Lo Sicco, Craig Fern, Jerry Shapiro. Central serous chorioretinopathy after scalp and eyebrow intralesional triamcinolone acetonide injections: Report of two cases. JAAD Case Rep . 2024 Jul 14:51:86-91. doi: 10.1016/j.jdcr.2024.06.034. eCollection 2024 Sep.

Season 8, Episode 3. Understanding Alopecia Neoplastica: A Deep Dive into Hair Loss from Metastatic Breast Cancer Oct 21, 2024

Welcome to another insightful episode of the Evidence-Based Hair Podcast with Dr. Jeff Donovan, a dermatologist and hair loss specialist. As the director of the Donovan Hair Academy, Dr. Donovan is dedicated to educating the public and practitioners about hair loss through comprehensive training programs.

In this episode, Dr. Donovan explores a fascinating study from the Brazilian Annals of Dermatology, focusing on the trichoscopic features of alopecia neoplastica caused by breast cancer metastases. Alopecia neoplastica, a type of hair loss linked to neoplastic processes, can sometimes resemble alopecia areata, but presents with distinct trichoscopic patterns. Dr. Donovan discusses the study's findings on the blood vessel patterns and color variations that are key indicators of this condition.

Join us as we delve into the clinical case of a patient with metastatic breast cancer presenting with alopecia neoplastica. Discover the significance of early detection and how trichoscopy can aid in diagnosing and managing this complex form of hair loss.

Tune in next week as we explore the rare side effect of central serous chorioretinopathy from steroid injections, and continue our journey of empowering clinicians and patients through education.

STUDIES REFERENCED IN THIS EPISODE

Bruno Simão Dos Santos, Eduardo César Diniz Macêdo, Bruna Nascimento Arruda Scabello, Patrícia Porto de Oliveira Grossi, Neusa Yuriko Sakai Valente. Dermoscopy of neoplastic alopecia secondary to cutaneous metastasis from breast carcinoma. An Bras Dermatol. 2024 Sep-Oct;99(5):742-745. doi: 10.1016/j.abd.

Season 8, Episode 2: Exploring Diphencyprone Use for Alopecia Areata During Pregnancy Oct 14, 2024

Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist, Dr. Jeff Donovan. As the director of the Donovan Hair Academy, Dr. Donovan is committed to educating both the public and hair loss practitioners through comprehensive programs like the Evidence-Based Hair Fellowship (EBHF).

In this episode, Dr. Donovan delves into a compelling case report from JAAD Case Reports that explores the use of diphencyprone (DPCP) for treating alopecia areata during pregnancy. Traditionally contraindicated in pregnancy, DPCP is a topical treatment that induces an allergic reaction on the scalp to promote hair regrowth in patients with alopecia areata. Dr. Donovan discusses a unique case where a patient opted to continue DPCP treatment during her pregnancies, resulting in minimal hair loss without any adverse effects on her pregnancies or babies.

Dr. Donovan emphasizes the significance of this study in contributing to the limited data available on DPCP use during pregnancy. While the findings are promising, he cautions that more research is needed before making broad recommendations for DPCP use during pregnancy.

Join Dr. Donovan next week too as he explores the trichoscopy of alopecia neoplastica from breast cancer in another enlightening episode of the Evidence-Based Hair Podcast. Don't miss this opportunity to expand your knowledge and engage in meaningful discussions about hair loss treatment and research.

STUDIES REFERENCED IN THIS EPISODE:

Desai DD et al. Use of diphenylcyclopropenone for alopecia areata treatment during pregnancy. JAAD Case Rep. 2024 Apr 19:48:88-89.

Berth-Jones et al. Diphencyprone is not detectable in serum or urine following topical application. Acta Derm Venerol 1994; 74: 312-3.

Season 8, Episode 1: Navigating JAK Inhibitors and Pregnancy: Insights and Implications Oct 07, 2024

Welcome to the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist Dr. Jeff Donovan. As the director of the Donovan Hair Academy, Dr. Donovan is dedicated to educating both the public and practitioners about hair loss through comprehensive training programs like the Evidence-Based Hair Fellowship.

In this episode, Dr. Donovan delves into the critical topic of JAK inhibitors and their safety during pregnancy. He explores a pivotal study published in Drug Safety that examines pregnancy outcomes in patients treated with Upadacitinib, a JAK inhibitor used for various inflammatory disorders, including alopecia areata.

The episode provides an in-depth analysis of data from clinical trials and post-marketing reports, highlighting the impact of JAK inhibitors on pregnancy outcomes, such as congenital anomalies and live births. Dr. Donovan discusses the importance of understanding the safety of these medications in pregnancy and emphasizes the need for more research in this area.

Listeners will gain valuable insights into the complexities of managing hair loss treatments during pregnancy and the challenges faced by patients and clinicians alike. Dr. Donovan also shares promising findings and case studies involving other JAK inhibitors, offering a comprehensive overview of the current landscape and future directions in this field.

Join us for this informative episode as Dr. Donovan addresses a pressing concern in the world of hair loss and pregnancy, providing expert analysis and guidance for both practitioners and patients.

REFERENCES

Uma Mahadevan et al. Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. Drug Saf . 2024 Oct;47(10):1039-1049. doi: 10.1007/s40264-024-01454-0. Epub 2024 Jul 15.

Megan E B Clowse et al. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Saf . 2016 Aug;39(8):755-62. doi: 10.1007/s40264-016-0431-z.

Mahadevan U et al. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. Inflamm Bowel Dis. 2018 Nov 29;24(12):2494-2500. doi: 10.1093/ibd/izy160.

Season 8 Preview Oct 01, 2024

Welcome back to Season 8 of the Evidence-Based Hair Podcast! I'm Dr. Jeff Donovan, a dermatologist and hair loss specialist. Join me each week as I review groundbreaking studies that are transforming our understanding of hair loss and influencing clinical practices.

This season, we'll delve into a variety of compelling topics including hair loss medications during pregnancy, JAK inhibitors like upadacitinib and baricitinib, and the use of terzepatide and metformin. We'll also explore conditions such as alopecia areata, androgenetic hair loss, CCCA, and dissecting cellulitis, and discuss their links to heart disease, thyroid disease, and breast cancer.

Episodes will be released every Monday, and you can also find video presentations on our Donovan Medical YouTube channel. Thank you for your continued interest, and we look forward to another exciting season!

Season 7, Ep 10: Topical JAK Inhibitors: How well do they work for FFA/LPP? Jun 24, 2024

Welcome back to the Evidence-Based Hair Podcast! This episode continues our June theme on JAK inhibitors, focusing on their topical use for treating frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP).

We'll delve into a groundbreaking study by Dr. Maryanne Senna and colleagues from Boston, examining the effectiveness and side effects of topical 2% tofacitinib for FFA and LPP. The study's results provide encouraging data, showing that about 31.6% of patients experienced improvement, and 60.5% saw disease stabilization.

Join us as we explore the potential of topical JAK inhibitors in managing scarring alopecia, their practical applications, and the implications for future treatment protocols. Don't miss our insightful discussion on this emerging therapy and how it could transform patient care.

Next month, we'll shift gears to discuss spironolactone and its role in treating androgenetic hair loss in women. Stay tuned!

STUDIES REFERENCED IN THIS EPISODE

Li-Chi Chen, Chino Ogbutor, Kristen J Kelley, Maryanne M Senna. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia. J Am Acad Dermatol. 2024 Jun;90(6):1260-1262. doi: 10.1016/j.jaad.2024.01.060. Epub 2024 Feb 2.

Yang C.C., Khanna T., Sallee B., Christiano A.M., Bordone L.A.: Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther 2018; 31:

Moussa A., Bhoyrul B., Asfour L., Kazmi A., Eisman S., Sinclair R.D.: Treatment of lichen planopilaris with baricitinib: a retrospective study. J Am Acad Dermatol 2022; 87: pp. 663-666.

Plante J., Eason C., Snyder A., Elston D.: Tofacitinib in the treatment of lichen planopilaris: a retrospective review. J Am Acad Dermatol 2020; 83: pp. 1487-1489.

Season 7, Episode 9: Exploring Topical JAK Inhibitors for Scarring Alopecia Jun 24, 2024

Welcome back to another episode of the Evidence-Based Hair Podcast. This week, we continue our June theme of JAK inhibitors, focusing on the use of topical JAK inhibitors for treating frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP).

In this episode, we delve into a significant study by Dr. Maryanne Senna and colleagues from Boston, exploring the effectiveness and side effects of topical 2% tofacitinib for LPP and FFA. The study, involving 41 patients, provides valuable statistics on improvement and stabilization rates, offering practical insights for clinical application.

We discuss the potential of topical JAK inhibitors, given their less systemic absorption compared to oral forms, and their specific relevance to scarring alopecia where inflammation is closer to the skin's surface. Despite some challenges with compounded topical formulations, the study's promising results highlight a third of patients showing improvement and over 60% achieving disease stabilization.

Join us as we wrap up our June series on JAK inhibitors and prepare for July, where we'll focus on the antiandrogen spironolactone and its use in androgenetic hair loss in women.

Thank you for tuning in, and I look forward to our next discussion on the Evidence-Based Hair Podcast.

STUDY REFERENCED

Li-Chi Chen, Chino Ogbutor, Kristen J Kelley, Maryanne M Senna. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia. J Am Acad Dermatol. 2024 Jun;90(6):1260-1262. doi: 10.1016/j.jaad.2024.01.060. Epub 2024 Feb 2.

Season 7, Episode 9: Baricitinib for Pediatric Alopecia Areata: Promising Results and Future Directions Jun 18, 2024

Welcome to another episode of the Evidence-Based Hair Podcast. In this episode, Dr. Donovan delves into an insightful study by Zhao and colleagues, published in the Journal of the European Academy of Dermatology and Venereology, titled "Baricitinib Therapy for Pediatric Patients with Severe Alopecia Areata."

This episode continues the June series dedicated to JAK inhibitors. Dr. Donovan highlights the increasing global use of these medications for treating severe alopecia areata, including the recent approvals of baricitinib and ritlicitinib.

The featured study examines the effectiveness and safety of baricitinib in treating children with severe alopecia areata, focusing on a small group of 10 patients aged between under two years to 13 years. The results reveal promising regrowth and mild side effects, underscoring the potential of baricitinib for younger patients.

Dr. Donovan discusses the broader implications of these findings, including the likelihood of future approvals for younger age groups and the importance of long-term safety data. He emphasizes the need for ongoing research and real-world studies to better understand the prolonged effects of JAK inhibitors.

Join Dr. Donovan next week for the final episode of the June series, where he will explore a study on the use of topical tofacitinib for treating lichen planopilaris and frontal fibrosing alopecia.

Season 7, Episode 8: Effectiveness of Generic Tofacitinib in Treating Alopecia Areata Jun 15, 2024

Welcome back to another episode of the Evidence-Based Hair Podcast! In this episode, we delve into a fascinating study on the use of generic tofacitinib for treating alopecia areata.

This study, published in the Archives of Dermatologic Research, explores the effectiveness and safety of generic tofacitinib. With the recent availability of this cost-effective alternative in Canada, the study provides valuable insights into whether switching from brand name options (Xeljanz) is a viable choice for patients.

The retrospective study included 20 patients with advanced alopecia areata, and the results were promising. A significant number of patients experienced noticeable improvements in hair regrowth, with low incidence of side effects. This episode discusses the study's findings and the broader implications for treatment options in alopecia areata.

Join me as we explore how this study might change the landscape of hair loss treatment and what it means for patients and practitioners alike. Don't miss next week's episode, where we'll discuss the use of baricitinib in young children.

STUDY REFERENCED

Jian J et al. Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study. Arch Dermatol Res. 2024 May 11;316(5):154. doi: 10.1007/s00403-024-02879-4.

Season 7, Episode 7: Infectious Diseases and Vaccinations Among JAK Inhibitor Users Jun 04, 2024

In this June series of the podcast, we focus on JAK inhibitors. This episode kicks off with a detailed review of an Italian study published in Expert Opinion in Drug Safety, which examines the incidence and management of infections in patients with alopecia areata treated with JAK inhibitors. Dr. Donovan discusses the findings, emphasizing that about one in three patients on JAK inhibitors may develop infections, highlighting the need for careful monitoring and potential treatment pauses.

Additionally, Dr. Donovan reviews a study from New York in Archives of Dermatologic Research, which reveals low vaccination rates among patients with immune-mediated diseases on biologics and JAK inhibitors. The study underscores the importance of pre-treatment vaccinations to mitigate infection risks.

Join us next week as we explore the efficacy and cost benefits of generic tofacitinib in managing alopecia areata, part of our ongoing series on JAK inhibitors. Stay tuned for more insights and expert analysis on the Evidence-Based Hair Podcast.

STUDIES REFERENCE IN THIS WEEK'S EPISODE

Giacomo Caldarola et al. Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment. Expert Opin Drug Saf. 2024 May 8:1-5.

Hren MG and Khattri S. Low rates of vaccination among atopic dermatitis, alopecia areata, psoriasis, and psoriatic arthritis patients on biologics. Arch Dermatol Res. 2024 May 25;316(6):285

Season 7, Episode 6: Topical Minoxidil for Facial Hair Enhancement May 27, 2024

In this episode, Dr. Jeff Donovan, a dermatologist and hair loss specialist, examines the effect of topical minoxidil in enhancing beard hair growth in men

Dr. Donovan focuses on a study published in Sage Open Medicine Case Reports titled, "Facial Hair Enhancement with Minoxidil and Off-Label Use". This study highlights the impact of using topical minoxidil for beard hair growth. As a subject frequently questioned by men worldwide, understanding the benefits, side effects, and the result of its use is vital.

A noteworthy part of this study was that it compared the use of topical minoxidil by two identical twins. Only one of the twins applied minoxidil on his face, and as early as the first month, finer, lighter-colored hairs appeared on his beard and mustache. He experienced hair shedding for a few months but still showed overall improvement in hair density and count after using minoxidil for 16 months.

Despite mild side effects such as skin dryness and hypertrichosis on ears and forehead, as well as increased body hair in other areas, the study shows that minoxidil can be an effective strategy for males wishing to enhance their facial hair. The patient in the case report switched to topical minoxidil foam due to dry flakiness caused by the solution, suggesting that the foam might be a preferable choice for some users.

To sum up, this 16-month-long study provides valuable insights on the potential effectiveness of using minoxidil for beard growth. Despite the side effects and need for more long-term data, the results suggest that it is a reasonably safe and potentially helpful approach for those who desire to improve their facial hair density.

Season 7, Episode 5: Alcohol Hangover and Hair Discoloration May 20, 2024

In this episode, we will dive into fascinating recent studies about the side effects of Minoxidil, a widely-known medication for hair loss treatment.

This podcast highlights new research regarding what Dr. Donovan calls "the OMAHA effect" (ORAL MINOXIDIL ALCOHOL HANGOVER ASSOCIATION), the surprising association between oral minoxidil use and exacerbated alcohol hangover symptoms. This phenomenon challenges previous conceptions in the medical field and warrants further investigation into potential implications for patients using oral Minoxidil.

However, though intriguing, the data about the OMAHA effect lacks detailed and quantitative information about the patients involved and their experiences. This calls for more precise and extensive research on the matter. Dr. Donovan emphasizes the need to gather more information before this knowledge can lead to changes in medical practice.

Moving forward, the episode also examines another study analyzing the association between topical Minoxidil and hair discoloration. This study equips you with more concrete data, reporting that about one-fourth of patients using Minoxidil perceive that the treatment has led to their hair graying. Despite the product monograph advising patients to stop minoxidil use when hair discoloration is noticed, the podcast argues that this abrupt termination might not be practical as patients risk losing the new hair growth achieved with Minoxidil when they stop the treatment.

Overall, this discussion underscores how hair graying and discoloration, like hair loss, also significantly impacts individuals' lives. As researchers dedicate more attention to understanding these issues, expect more practical guidelines and breakthroughs in combatting them.

Join Dr. Donovan every week for insightful discussions about ground-breaking studies relevant to hair loss and its treatment. Stay tuned for our next episode where we look into topical Minoxidil use for beard growth.

Season 7, Episode 4: Views of Dermatology Practitioners on Oral Minoxidil May 13, 2024

In this episode, we dive into a thought-provoking study by Sanfilippo and Friedman, "Survey of Dermatology Practitioners' Opinions and Prescribing Habits of Oral Minoxidil for the Treatment of Androgenetic Hair Loss".

The study provides valuable insights into the perceptions of practitioners on oral minoxidil, an increasingly popular option for treating hair loss.

We discuss the results of this survey and compare it with previous studies, shedding light not only on the effectiveness of oral minoxidil but also on the practitioners' comfort level in prescribing it and patients' satisfaction with its results.

The pulse of the global community and the evidence provided by well-conducted studies play a significant role in shaping our understanding of oral minoxidil. There's a critical need for long-term evaluations and more comprehensive studies to establish its effects and side effects over years of use.

Stay tuned for more in-depth discussions as we continue to explore the realm of hair loss treatments.

And don't forget, if you want to immerse yourself in the study of hair loss and acquire advanced clinical and problem-solving skills, consider applying for a training position in the Evidence-Based Hair Fellowship, the world's most comprehensive program for physicians and allied health professionals.

Season 7, Episode 3: Oral vs Topical Minoxidil for Androgenetic Alopecia May 07, 2024

In this episode of the Evidence-Based Hair Podcast hair loss specialist Dr. Jeff Donovan breaks down the findings of a recent study comparing oral minoxidil and topical minoxidil in the treatment of male androgenetic alopecia. Published in JAMA Dermatology, the study challenged popular opinions by revealing similar performance between the two types of minoxidil, putting a spotlight on the importance of robust evidence from randomized controlled trials.

Interestingly, Dr. Donovan examined the historical usage of oral minoxidil, once a blood pressure medication, in treating hair loss and the subsequent need for more rigorous studies to solidify its effectiveness. The episode also covers the surprising conclusion that oral minoxidil did not significantly outperform its topical counterpart, contrary to what the mainstream assumes.

Diving deeper into the debate, Dr. Donovan explored differing perspectives derived from the Pantchprateep et al and Penha et al studies of oral minoxidil. Where the Panchaprateep et al study suggested that all patients saw some improvement, the Penha et al study showed that not all participants experienced the same positive results.

In an in-depth examination of the 'Oral Minoxidil versus Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial', the potential side effects, including minor adverse effects of both treatments were also discussed. While not definitive in recommending one treatment over the other, the episode sparks stimulating discussions around the efficacy of oral minoxidil, its comparison to topical minoxidil, and the potential of randomized controlled trials in determining the optimal treatment for male androgenetic hair loss.

STUDIES REVIEWED IN THIS EPISODE

Penha MA et al. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol . 2024 Apr 10:e240284. doi: 10.1001/jamadermatol.2024.0284. Online ahead of print

Panchaprateep et al. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther. 2020 Dec;10(6):1345-1357

Season 7, Episode 2: Drug-Induced Alopecia Areata Apr 28, 2024

This episode is dedicated to a fascinating subject – drug-induced alopecia areata. In addition to genetic factors, alopecia areata is also influenced by environmental factors such as infections and medications. In this episode, Dr Donovan highlights two studies: “A Cross-Sectional Analysis of Medications Used by Patients Reporting Alopecia Areata on the FDA Adverse Events Reporting System” by Ravapati et al and “Drug-Induced Alopecia Areata: A Systematic Review” by Ezemma et al. These studies present an intensive exploration of drugs possibly causing alopecia areata.

Studies show that monoclonal antibodies are common culprits, and reports of drug-induced alopecia areata are rising every over time.

Surprisingly, it has been observed that the onset of drug-induced alopecia areata could be delayed by as much as a year. Also, patients who discontinued the alleged drug stimulating alopecia areata experienced regrowth of hair, while those who didn't, failed unless treated.

Email is info@donovanhairacademy.com or visit our website www.donovanhairacademy.com.

Thank you all for joining. See you next week!

Season 7, Episode 1: Unraveling the Link Between Dupilumab and Cutaneous T-Cell Lymphoma Apr 22, 2024

Welcome to a new episode of the Evidence-Based Hair Podcast, where we discuss some questions surrounding the relationship between dupilumab and lymphoma. This episode dives deep into a study by Hasan and colleagues that explores the fascinating and somewhat controversial relationship between Dupilumab, a drug often used to treat atopic dermatitis patients with alopecia areata, and an increased risk of Cutaneous T-Cell Lymphoma (CTCL). Despite its potential benefits, does Dupilumab truly cause CTCL, or does it simply unmask the disease in patients who were previously misdiagnosed?

Using information from a vast database, authors examined whether patients using dupilumab showed an increased incidence of CTCL compared to those who did not. Findings suggest that users of the drug have a four-fold increased risk of CTCL.

While uncertainties remain on whether Dupilumab triggers lymphomas, causes benign lymphoid reactions, or accelerates existing CTCL, this episode underscores the drug's potential risks and the importance of careful diagnostics before prescribing it.

As we continue to gather data and debate the varying viewpoints, we invite you to join us in disentangling the complex relationship between Dupilumab and CTCL. Stay tuned for our next episode, where we explore drug-induced alopecia areata and the potential triggering effects of new monoclonal antibodies.

donovanmedical Edited• Season 7 of the Evidence Based Hair Podcast has started. This week I review several fascinating studies: The podcast can be accessed wherever you listen to your podcasts or via the DonovanMedical youtube channel.
REFERENCES IN THIS EPISODE Hasan I et al. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566-8. doi: 10.1016/j.jaad.2024.03.039. Online ahead of print.
Jfri A et al. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review. J Am Acad Dermatol . 2023 May;88(5):1164-1166. doi: 10.1016/j.jaad.2022.12.001. Epub 2022 Dec 5.
Espinosa ML et al. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol . 2020 Jul;83(1):197-199. doi: 10.1016/j.jaad.2020.03.050. Epub 2020 Mar 27.

Top 20 Hair Research Studies of 2023 Dec 22, 2023

This is a recording from the live webinar was conducted live December 13, 2023. This is an annual event that is held every year in mid-December celebrating the top hair research studies.

DERMATOPATHOLOGY

Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.

ANDROGENETIC ALOPECIA

Gupta AK et al.The relative efficacy of monotherapy with 5-alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta-analysis study. J Cosmet Dermatol. 2023 Jun 29

Jimenez-Cauhe J et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.

ALOPECIA AREATA

Gandhi et al.The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata. Dermatol Ther (Heidelb). 2023 Jan;13(1):285-298.

Li SJ et al. Experiencing Workplace Bullying in Patients with Alopecia Areata: A Cross-Sectional Survey Study. Skin Appendage Disord. 2023 Aug;9(4):258-261

Kazmi A et al. Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023 Apr 4;S0190-9622(23)00532-7.

King B et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023 May 6;401(10387):1518-1529.

George P et al. Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database., Dermatol Ther (Heidelb). 2023 Aug; 13(8): 1733–1746.

Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.

Chen J et al. The Incidence of Alopecia Areata in a COVID-19- Vaccinated Population: A Single-Center Review. Cureus 2023

TELOGEN EFFLUVIUM

Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol. 2023 Mar 8.

TINEA CAPITIS

Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.

COSMETIC DERMATOLOGY

Landau M et al. Nonscarring alopecia after temporal lifting technique with dermal fillers. JAAD Case Rep. 2023 May 12;37

FOLLICULITIS DECALVANS

Matard B et al. Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association. Br J Dermatol 2022 Dec;187(6):1026-1028.

DISCOID LUPUS

Fredeau L et al. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients. J Am Acad Dermatol. 2023 Mar;88(3):551-559.

DISSECTING CELLULITIS

Cajas-Garcia MS et al. Distinct presentations of scalp dissecting cellulitis manifesting with furrows and gyri. J Eur Acad Dermatol Venereol. 2023 Feb 3.

LICHEN PLANOPILARIS Lim SH et al. Prevalence and Incidence of Comorbid Diseases and Mortality Risk Associated with Lichen Planopilaris: A Korean Nationwide Population-Based Study. Clin Exp Dermatol. 2023 Jul 11;llad235

GENERAL SCARRING ALOPECIA

Kim SR et al. Association of Primary Cicatricial Alopecia with Subsequent Cardiovascular Disease. J Invest Dermatol. 2023 Nov 19:S

CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA

Joshi TP et al. Comorbidities in patients with central centrifugal cicatricial alopecia: a case-control study. Int J Dermatol. 2023 Nov 23.

ACNE KELOIDALIS NUCHAE

Lobato-Berezo A et al. Acne keloidalis nuchae: An international multicentric review of 79 patients. J Eur Acad Dermatol Venereol. 2023 Nov 1.

Season 6, Episode 7 (JAK Inhibitors in Skin Disease - Risk of Cardiovascular Disease, Blood Clots, and Acne) Dec 04, 2023

Season 6, Episode 6 (Alopecia Areata Triggered by COVID19 Vaccination) Nov 27, 2023

STUDIES REFERENCED IN THIS EPISODE

Pastukhova E et al. Alopecia Areata as a Sequela of COVID-19 Vaccination: A Systematic Review J Cutan Med Surg. 2023 Jan-Feb;27(1):64-65.

Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.

Genco L et al. Alopecia Areata after COVID-19 Vaccines. Skin Appendage Disord. 2023 Mar;9(2):141-143.

Season 6, Episode 5 (COVID 19 Infection and the Risk of Autoimmune Disease) Nov 22, 2023

STUDIES REVIEWED THIS WEEK:

Chang R et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023 Feb;56:101783

Tesch F et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol. 2023 Oct;42(10):2905-2914.

Lim SG et al. Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 JAMA Netw Open. 2023 Oct 2;6(10):e2336120.

Pastukhova E et al. Alopecia Areata as a Sequela of COVID-19 Vaccination: A Systematic Review J Cutan Med Surg. 2023 Jan-Feb;27(1):64-65.

STUDIES TO BE REVIEWED NEXT WEEK (PREVIEW)

Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.

Genco L et al. Alopecia Areata after COVID-19 Vaccines. Skin Appendage Disord. 2023 Mar;9(2):141-143.

Season 6 Episode 4 (Baricitinib for CCCA, LED laser therapy for CCCA) Nov 13, 2023

STUDIES REFERENCED IN THIS EPISODE:

Workman K and Kindred C (starts at 2:10). Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib. JAAD Case Rep. 2023 Jul 28:39:109-111.

Cook M et al (starts at 12:07). Use of low-level light therapy in management of central centrifugal cicatricial alopecia: A case series of four patients. Photodermatol Photoimmunol Photomed. 2023 Aug 23.

Season 6, Episode3 (Effect of Oral Minoxidil on Blood Pressure, Oral Minoxidil Use in Patients with High Blood Pressure and Arrhythmia) Nov 06, 2023

ARTICLES COVERED THIS WEEK

STUDY 1:

Ong M et al (starts at 5:12). Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study. J Am Acad Dermatol. 2023 Oct 13:S0190-9622(23)02976-6.

Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;

Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237

STUDY 2:

Imhof R et al (starts at 16:35). Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring. JAAD Int. 2023 Aug 12:13:50-52.

Ramos PM et al. Minoxidil 1 mg versus minoxidil 5 % topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol Jan 2020;82(1):252-253.

STUDY 3:

Jimenez-Cauhe J et al (starts at 24:27). Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.

Vano-Galvan S et al. Safety of low dose oral minoxidil for hair loss: A multicenter study of 1404 patients. JAAD 2021; 84: 1644-51.

Sanabria B et al. Adverse effects of low dose oral minoxidil for

androgenetic alopecia in 435 patients. JAAD 2021; 84: 1175-78.

ARITCLES COVERED NEXT WEEK (PREVIEW)

Cook M et al. Use of low-level light therapy in management of central centrifugal cicatricial alopecia: A case series of four patients. Photodermatol Photoimmunol Photomed. 2023 Aug 23.

Workman K and Kindred C. Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib. JAAD Case Rep. 2023 Jul 28:39:109-111

Season 6, Episode 2 (A Closer Look at Randomized Controlled Trials and Real World Non RCT Data) Nov 04, 2023

ARTICLES REFERENCED IN THIS EPISODE

Krauss A (starts at 12:44). Why all randomised controlled trials produce biased results. Ann Med. 2018 Jun;50(4):312-322.

Van Noreen R (starts at 15:33). Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? Nature. 2023 Jul;619(7970):454-458. Listen at https://youtu.be/_QLvzCr6nz4?feature=shared

Carlisle JB (starts at 16:28). False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. Anaesthesia. 2021 Apr;76(4):472-479.

PREVIEW STUDIES FOR NEXT WEEK (SEASON 6, EPISODE 3)

Ong M et al. Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study. J Am Acad Dermatol. 2023 Oct 13:S0190-9622(23)02976-6. doi: 10.1016/j.jaad.2023.10.010. Online ahead of print.

Jimenez-Cauhe et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.

Imhof R et al. Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring. JAAD Int. 2023 Aug 12:13:50-52.

Season 6 Episode 1 (Baricitinib Response Timing, Real World Study of Baricitinib) Oct 24, 2023

Studies Referenced in This Episode: Season 6 Episode 1

King B et al (starts at 4:07). When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023 Sep 14:ljad253.

Gargiulo L et al (starts at 30:22). Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J Dermatolog Treat. 2023 Dec;34(1):2268764.

Preview of Studies for New Week: Season 6 Episode 2

Krauss A. Why all randomised controlled trials produce biased results. Ann Med. 2018 Jun;50(4):312-322.

Carlisle JB. False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. Anaesthesia. 2021 Apr;76(4):472-479.

Van Noorden R. Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? Nature. 2023 Jul;619(7970):454-458. Listen at https://youtu.be/_QLvzCr6nz4?feature=shared

Reminder of December 1, 2023 Deadline For Evidence Based Hair FellowshipTraining Program for Hair Loss Practitioners Oct 01, 2023

On August 1, 2023, Dr Donovan announced the long awaited start of the Evidence Based Hair Fellowship training program. This is an online (virtual) training program for practitioners that wish to develop expertise in hair loss. The program runs Jan 2024 to August 2025 and participants meet once weekly for a three hour period (either on a Wednesday or a Thursday).

In this short recording, Dr Donovan updated listeners on the Evidence Based Hair Fellowship training program.

Interested participants may wish to watch video describing the full program at https://youtu.be/xWBT9sKWU_k?si=6TVCHw3lnNgb2_mk

or download the coarse syllabus at:

https://donovanmedical.com/donovan-hair-academy

Alopecia Areata Awareness Month - Recording from Sept 6 2023 Live Public Webinar Sep 10, 2023

Alopecia Areata Awareness Month - Recording from Sept 6 2023 Live Public Webinar hosted by Dr Donovan.

Question 1 (starts at 3:50): Is the rate of alopecia areata going up ?

Question 2 (starts at 7:45). What blood tests should be ordered for someone with alopecia areata?

Question 3 (starts at 11:58). Do JAK inhibitors cure alopecia areata?

Question 4 (starts at 15:45). What treatments are possible for eyelash loss?

Question 5 (starts at 17:53). What other medical problems do patients with alopecia areata have?

Question 6 (starts at 20:29). My son is 3 years old and Alopecia. 1 year ago, hair loss started and his hair and eyebrows completely fell out. In the tests , it was determined that his intestinal flora was very disordered and he has lactose and gluten intolerance. There are some doctors who have found that Intestinal Flora Disorder and Leaky Gut Syndrome can cause some autoimmune diseases. I would like to know your thoughts on this subject.

Question 7 (starts at 26:58). Should I ask for a biopsy to prove the diagnosis of alopecia areata?

Question 8 (starts at 29:01). I am a 37 year old female and have alopecia areata. Will I pass this on to my children?

Question 9 (starts at 31:48). Does stress cause alopecia areata? I hear mixed views.

Question 10 (starts at 35:16). My 3 year old developed a small area of alopecia over the summer. What treatment is considered best?

Question 11 (starts at 41:12). Does low vitamin D make alopecia worse?

Question 12 (starts at 43:43). Myalopecia areata is becoming scarring. How is this possible?

Question 13 (starts at 47:13). Do you see loss of efficacy over time of JAK inhibitors and if so what would be the reason

Season 5, Episode 6 (Selenium Toxicity, Alopecia Neoplastica, Lymphema Distichiasis Syndrome, Eyebrow Hypotrichosis, Seasonal Shedding) Aug 30, 2023

Season 5 Ep 6

Season 5, Episode 5 (CCCA Prognosis, CCCA in Males, Anagen Hairs in LPP, EPDS and NMSC and FD in Females) Aug 21, 2023

STUDIES REFERENCED IN THIS EPISODE

Onamusi T et al (starts at 8:58). Clinical factors and hair care practices influencing outcomes in central centrifugal cicatricial alopecia. Arch Dermatol Res. 2023 May 15. doi: 10.1007/s00403-023-02630-5. Online ahead of print.

Erinolaoluwa F et al (starts at 11:59). Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Reports Feb 2020

Jackson TK et al (starts at 15:40). Central Centrifugal Cicatricial Alopecia in Males. J Am Acad Dermatol. 2023 Jul 24:S0190-9622(23)02399-X.

Melo RR et al (starts at 21:45). Positive Anagen Pull Test Predicting Lichen Planopilaris Activity. Dermatol Pract Concept. 2023 Jul 1;13(3):e2023140.

Shamloul N et al (starts at 29:14). Incidence and time to development of malignancies arising on the scalp of patients with erosive pustular dermatosis based on sex: A retrospective analysis. J Am Acad Dermatol. 2023 Jun 13;S0190-9622(23)01111-8.

Negbenebor NA et al (starts at 34:45). Nonmelanoma skin cancer in the setting of erosive pustular dermatosis of the scalp: A case series and comment on management implications. Dermatol Ther. 2022 Jul;35(7):e15584. doi: 10.1111/dth.15584. Epub 2022 May 28.

Sarkis A et al (starts at 41:54). Folliculitis Decalvans in women: a retrospective multicenter study of 150 patients. J Eur Acad Dermatol Venereol. 2023 Aug 18.

Vañó-Galván S et al (starts at 43:39). Folliculitis decalvans: a multicentre review of 82 patients. J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1750-7.

Season 5, Episode 4 (Switching JAK Inhibitors, Ritlecitinib in Adolescents, VTE Risk in AT/AU, Habit Replacement Therapy in TTM) Aug 14, 2023

STUDIES REFERENCE IN THE EPISODE

SWITCHING FROM TOFACITINIB TO BARICITINIB

Kazmi A et al (starts at 12:33). Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023 Apr 4;S0190-9622(23)00532-7.

RITLECITINIB IN ADOLESCENTS

Hordinsky M et al (starts at 21:31). Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023 Jul 17.

RISK OF INFECTIONS, CANCER, HEART DISEASE AND BLOOD CLOTS IN AT/AU

George P et al (starts at 36:08). Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database., Dermatol Ther (Heidelb). 2023 Aug; 13(8): 1733–1746.

Schneeweiss MC et al (starts at 37:36). Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatol. 2021 Jul 1;157(7):805-816.

MARKERS OF VENOUS THROMBOEMBOLISM IN ALOPECIA AREATA

Sudnik W et al (starts at 57:40) . The role of selectins in alopecia areata. Postepy Dermatol Alergol. 2015 Feb;32(1):27-32.

Shakoei S et al (starts at 58:23). Coagulation status in patients with alopecia areata: a cross-sectional study. Ital J Dermatol Venerol. 2021 Oct;156(5):588-592.

Waśkiel-Burnat A et al (starts at 59:30). Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about? Dermatol Ther (Heidelb). 2023 Aug;13(8):1847-1855.

HABIT REPLACEMENT THERAPY FOR TRICHOTILLOMANIA

Moritz S et al (starts at 1:04:34). Self-Help Habit Replacement in Individuals With Body-Focused Repetitive Behaviors: A Proof-of-Concept Randomized Clinical Trial. JAMA Dermatol. 2023 Jul 19;e232167.

LINK TO VIDEO on HRT DEMONSTRATION https://clinical-neuropsychology.de/habit-replacement-en/#sthash.J6iQiYRi.dpuf

Season 5, Episode 3 (Ranking of Finasteride and Minoxidil Protocols for FPHL, Follow up to New York Times Aug 2022 Article, Periorbital Edema from Oral Minoxidil, TE from Anticonvulsant Medications) Aug 08, 2023

Season 5, Episode 2 (CVG secondary to Psoriasis, Hair Loss from Temporal Lifts, Oral minoxidil Lung Disease, PTSD & Autoimmunity, Laser Hair Removal & Behcet’s) Jul 25, 2023

NON SCARRING ALOPECIA AFTER HYALURONIC ACID TEMPORAL LIFTING TECHNIQUES

Landau M et al (starts at 9:05). Nonscarring alopecia after temporal lifting technique with dermal fillers. JAAD Case Rep. 2023 May 12;37:30-34

Coimbra D.D., and de Oliveira B.S (starts at 10:17). Supra-auricular lifting with fillers: new technique. J Cosmet Dermatol. 2016;8(4):328–335.

CUTIS VERTICES GYRATA DUE TO PSORIASIS

Garcia-Rodriquez V et al (starts at 25:19). Cutis verticis gyrata secondary to scalp psoriasis. Int J Dermatol. 2023 Jun 4.

ORAL MINOXIDIL ASSOCIATED HYPERSENSITIVITY PNEUMONITIS

Takekosh D et al (starts at 32:35). Minoxidil-induced lung disease, masquerading as hypersensitivity pneumonitis. Respir Med Case Rep. 2023 Apr 29;43:101861.

PTSD AND AUTOIMMUNE DISEASE

Hsu TW et al (starts at 43:40). Risk of autoimmune diseases after post-traumatic stress disorder: A nationwide cohort study. Eur Arch Psychiatry Clin Neurosci. 2023 Jun 15.

Song H et al (starts at 49:18). Association of Stress-Related Disorders With Subsequent Autoimmune Disease. JAMA. 2018 Jun 19;319(23):2388-2400.

Dai Y-X et al (starts at 51:00). Posttraumatic Stress Disorder and the Associated Risk of Autoimmune Skin Diseases: A Nationwide Population-Based Cohort Study. Psychosom Med. 2021 Apr 1;83(3):212-217.

PATHERGY IN PATIENTS WITH BEHCET’S DISEASE RECEIVIGING LASER HAIR REMOVAL R

Nicolau et al (starts at 53:07). Pathergy-like reaction induced by laser hair removal in a patient with Behçet disease. Reumatismo. 2023 Jul 17;75(2).

Van der Ree-Pellikaan C et al (starts at 1:01:48). Oral ulcerations after placement of orthodontic braces and skin pustules after laser hair removal: novel inducers of pathergy reactions in new-onset Behçet's disease. BMJ Case Rep. 2016 Mar 7;2016:bcr2014209208. doi: 10.1136/bcr-2014-209208.

Season 5 Episode 1 (LPP Disease Associations, LPP & Thyroid, Side Effects of HCQ, Genetic Basis of Male FFA, FFA Prevalence/Incidence) Jul 17, 2023

DISEASE ASSOCIATIONS IN FRONTAL FIBROSING ALOPECIA

Conic et al. Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders. J Eur Acad Dermatol Venereol 2021 Nov;35(11):e826-e828.

Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.

Lim SH Prevalence and Incidence of Comorbid Diseases and Mortality Risk Associated with Lichen Planopilaris: A Korean Nationwide Population-Based Study. Clin Exp Dermatol. 2023 Jul 11;llad235

THE RELATIONSHIP BETWEEN LPP AND HYPOTHYROIDISM

Joshi TP et al. Association of lichen planopilaris with hypothyroidism: a systematic review and meta-analysis. Int J Dermatol. 2023 Jul 10.

SIDE EFFECTS OF HYDROXYCHLOROQUINE IN PATIENTS WITH SCARRING ALOPECIA

Ezemma O et al. Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review. Int J Dermatol. 2023 Apr 10. doi: 10.1111/ijd.16660. Online ahead of print

GENETICS OF MALE FRONTAL FIBROSING ALOPECIA

Rayinda T et al. Shared Genetic Risk Variants in Both Male and Female Frontal Fibrosing Alopecia. J Invest Dermatol. 2023 May 19;S0022-202X(23)02068-7.

INCIDENCE AND PREVALENCE OF FRONTAL FIBROSING ALOPECIA

Lavian J et al. Incidence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. Dermatol Online J. 2021 Aug 15;27(8).

Trager MH et al. Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. J Am Acad Dermatol 2021 Apr;84(4):1166-1169

Carmona-Rodriquez M et al. Frontal Fibrosing Alopecia: An Observational Single-Center Study of 306 Cases. Life (Basel). 2023 Jun 8;13(6):1344.

Season 4, Episode 8 (Isotretinoin for SD, Iron Therapy, Memantine for TTM, Antifungal Resistance Apr 09, 2023

Season 4, Episode 8

Season 4, Episode7 (Tinea with baricitinib, ADHD and AA, Upadacitinib for AA, Baricitinib 52 week data, micro needling for MPHL) Apr 05, 2023

Season 4, Episode 7 Data

Season 4, Episode 6 (Scalp Neuropathy in DMS, Scurvy, Cutaneous Pili Migrans, Quiz Case, Beethoven’s Hair) Mar 30, 2023

Season4, Episode 6

Season 4, Episode 5 (Hair Loss after COIVD Vaccines, FD in DEB, New DSC ”CVG” Variants, DSC After HT, DLE to SLE Progression) Mar 22, 2023

Season 4, Episode 5

Season 4, Episode 4 (COVID hair loss, TE from anti-CGRP migraine meds, tinea capitis, oral minoxidil for traction alopecia Mar 13, 2023

Season 4 Episode 4

COVID RELATED TE

Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol. 2023 Mar 8.

M Alharbi et al. Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia. J Family Med Prim Care. 2022 Oct;11(10):6056-6060.

Tahmaz A et al. [The Evaluation of Long Coronavirus Disease Symptoms at Ninth Month from a Hospital in Türkiye]. .Mikrobiyol Bul. 2022 Oct;56(4):657-666.

Saber M et al. Scalp capillarectasia as a trichoscopic sign of COVID-19-associated telogen effluvium. J Cosmet Dermatol. 2023 Mar 9

Lv S et al. A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection Clin Cosmet Investig Dermatol. 2021; 14: 385–387. Published online 2021 Apr 16.

Willimann B, et al. Hair pain (trichodynia): frequency and relationship to hair loss and patient gender. Dermatology. 2002

HAIR LOSS FROM ANTI-CGRP THERAPIES

Ruiz M et al. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review. Cephalalgia. 2023 Feb;43(2):3331024221143538.

Sessa M and Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs 2021; 35: 215–227

Evers S and Wald S. Effluvium and alopecia associated with monoclonal calcitonin gene-related peptide antibody use. Headache. 2023 Jan;63(1):165-167.

ORAL MINOXIDIL FOR TRACTION ALOPECIA

Awad A et al. Low-dose oral minoxidil improves hair density in traction alopecia. J Am Acad Dermatol. 2023 Feb 24;S0190-9622(23)00278-5.

Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther. 2018 Nov;31(6):e12707.

Kim and Craiglow. Treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022 Apr 1;23:112-113.

TINEA CAPITIS WORK UP AND TREATMENT IN PEDIATRICS

Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.

Season 4 Episode 3 (Spironolactone for FPHL, Oral Minoxidil for Nails, Histology of AA vs AGA, AAI, Work Productivity in AA) Mar 07, 2023

Season 4, Episode 3

Season 4, Episode 2 (Scalp Bx for Black Women, Oral Minoxidil for Chemotherapy Hair Loss, Folliculotropic MF, Atrichia with Papular Lesions, MTX and Liver Fibrosis) Mar 01, 2023

STUDIES REFERENCED

ROLE OF SCALP BIOPSIES IN BLACK WOMEN WITH HAIR LOSS

Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.

ORAL MINOXIDIL IN CHEMOTHERAPY RELATED HAIR LOSS

Kang J et al. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study. J Am Acad Dermatol 2022 Dec 13;S0190-9622(22)03261-3.

FOLLICULOTROPIC MYCOSIS FUNGOIDES

Paolino G et al. Widespread and eruptive comedonal lesions with alopecia. JAAD Case Rep . 2022 Nov 1;31:23-26.

Kreutzer and Effendy. Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides. Dermatol Ther (Heidelb). 2020 Oct;10(5):1175-1180

Gallo G et al Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement. Scientific Reports. 2021 May 18;11(1):10555.

ATRICHIA WITH PAPULES LESIONS

Boisen J et al. Atrichia With Papular Lesions Confirmed via Genetic Testing: A Case Report. Cureus 2022 Dec; 14(12): e32562.

Zlotogorski A, Panteleyev AA, Aita VM, Christiano AM. Clinical and molecular diagnostic criteria of congenital atrichia with papular lesions. J Invest Dermatol 2002; 118: 887–890

Yip L, Horev L, Sinclair R, et al. Atrichia with papular lesions: a report of three novel human hairless gene mutations and a revision of diagnostic criteria. Acta Derm Venereol 2008; 88(4): 346–349.

Bergman R et al. The alopecias associated with vitamin D-dependent rickets type IIA and with hairless gene mutations: a comparative clinical, histologic, and immunohistochemical study. Arch Dermatol. 2005 Mar;141(3):343-51.

METHOTREXATE AND LIVER FIBROSIS

Atallah E et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol . 2023 Jan 23;S0168-8278(23)00020-X.

Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015;45(2):156–162

Cheema HI et al. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. J Investig Med. 2022 Oct;70(7):1452-1460.

Season 4, Episode 1 (HCQ and Retinopathy Risk, FD Microbiome, LDN for LPP, TNF Inhibitors for DSC) Feb 20, 2023

STUDIES REFERENCED PATHOLOGY OF NON SCARRING AND SCARRING ALOPECIA Amanda Araujo Dos Reis Botega et al. Scarring versus Non-Scarring Alopecia: An Interobserver Histopathological Reproducibility Study Skin Appendage Disord. 2023 Jan;9(1):34-41. doi: 10.1159/000526966. Epub 2022 Nov 25. HYDROXYCHLOROQUINE AND RETINOPATHY RISK Ronald B Melles RB et al. Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. Ann Intern Med. 2023 Jan 17. LOW DOSE NALTREXONE IN LICHEN PLANOPILARIS Lajevardi et al. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled trial. J Dermatol Treat. Jun 2020 Hamel RK et al. Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study. Cureus Jan 2023. Toledo-Pastrana et al. Perifollicular Erythema as a Trichoscopy Sign of Progression in Frontal Fibrosing Alopecia. Int J Trichology. 2013 Jul-Sep; 5(3): 151–153. ACTINIC LICHEN PLANOPILARIS Lalagianni N et al. Actinic lichen planopilaris: a new variant of lichen planopilaris triggered by ultraviolet radiation. Clin Exp Dermatol. 2023 Feb 2;48(2):158-160. FOLLICULITIS DECALVANS MICROBIOME STUDIES Moreno-Arrones OM et al. Folliculitis decalvans has a heterogeneous microbiological signature and impaired immunological response. Dermatology. 2023 Jan 30. Moreno-Arrones et al. Folliculitis decalvans microbiologic signature is specific for disease clinical phenotype. J Am Acad Dermatol. 2021 Nov;85(5):1355-1357. TNF INHIBITORS IN DISSECTING CELLULITIS Alzahrani M et al. Treatment of dissecting cellulitis of the scalp with tumor necrosis factor inhibitors: a retrospective multicenter STUDY. Clin Exp Dermatol. 2023 Jan 26;llad036.

Season Finale (PART 2 of 2): Top 20 Hair Research Studies of 2022 Dec 23, 2022

The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in hair shedding, scarring alopecia, seborrheic dermatitis and hair straighteners (studies 12 to 20). Studies 1 to 11 are found in Part 1 (season 3 episode 9)

STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19

STUDY 12: Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.

STUDY 13: Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022

STUDY 14: Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.

STUDIES IN SCARRING ALOPECIA

STUDY 15: Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016

STUDY 16: Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan

STUDY 17: Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.

STUDY 18: Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.

STUDIES IN VARIOUS TOPICS

STUDY 19: Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.

STUDY 20: Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.

STUDIES IN PART 1 of PODCAST

STUDIES IN AGA

STUDY 1: Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645

STUDY 2: Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.

STUDY 3: Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;

STUDY 4: Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.

STUDY 5: Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.

STUDY 6: Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.

STUDY 7: Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36

STUDY 8: Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.

STUDY 9: Liang X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.

STUDIES IN ALOPECIA AREATA

STUDY 10: King B et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.

STUDY 11: Anna Waśkiel-Burnat et al. Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.

Season Finale (PART 1 of 2): Top 20 Hair Research Studies of 2022 Dec 23, 2022

The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in androgenetic alopecia and alopecia areata (studies 1 to 11). Studies 12 to 20 are found in Part 2 (season 3 episode 10)

STUDIES IN FEMALE PATTERN HAIR LOSS AND MALE PATTERN HAIR LOSS